BIO INTERNATIONAL CONVENTION 2018 - Export Business France
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
IN
PARTNERSHIP
WITH:
BIO INTERNATIONAL
CONVENTION 2018
FRENCH DELEGATION
USA – BOSTON / JUNE 4 – 7, 2018
BUSINESS FRANCE
www.businessfrance.fr
Business France is the national agency supporting the
international development of the French economy, responsible
for fostering export growth by French businesses, as well as
promoting and facilitating international investment in France.
It promotes France’s companies, business image and
nationwide attractiveness as an investment location, and
also runs the V.I.E international internship program.
Business France has 1,500 personnel, both in France and in
64 countries throughout the world, who work with a network
of public- and private-sector partners.
For further information, please visit:
www.businessfrance.fr
2
FLOOR PLAN
Auvergne - R hône - Alpes
WITH THE SUPPORT OF OUR PROUD SPONSORS
3Nothing
but blue
skies
BlueReg, your partner for success
BlueReg is an international consultancy company Our expert teams provide full service support and
for the pharmaceutical industry specialising individually tailored solutions throughout products’
in development, regulatory affairs, quality lifecycle, including development, submission,
management and pharmacovigilance. approval, post-approval and launch.
SOPHIA ANTIPOLIS +33 (0)4 22 00 01 00
PARIS +33 (0)1 82 73 10 00
contact@blue-reg.com LONDON +44 (0) 3333 112131
www.bluereg-group.com NEW YORK +1 (347) 7081498ARE YOU
HIRING?
C O N TA C T O U R G L O B A L H Q s I N B O S T O N
+ 1 8 5 7 5 74 0 3 9 4
R E C R U I T I N G @ PAC T PA R T N E R S .C O M
W W W. P A C T A N D P A R T N E R S . C O MEXHIBITORS LIST
SPONSORS Ans Biotech........................................................ 29
Axelia Partners................................................... 10 Aptys Pharmaceuticals...................................... 29
Bluereg Pharma Consulting.............................. 10 Ariana Pharmaceuticals..................................... 30
Pact and Partners - Life Sciences Recruitments.. 11 Atlanthera........................................................... 30
Atlantic Bone Screen......................................... 31
B Cell Design..................................................... 31
PARTNERS Balmes Transplantation..................................... 32
Alsace Biovalley................................................. 13
Banook................................................................ 32
SATT Aquitaine - Aquitaine Science Transfert.. 13
Bioaster............................................................... 33
Assistance Publique
Biocellvia............................................................ 33
Hôpitaux de Paris (ap-hp)................................. 14
Biodol Therapeutics.......................................... 34
Atlanpole Biotherapies..................................... 14
Biose Industrie................................................... 34
SATT AXLR......................................................... 15
C4Diagnostics.................................................... 35
Biopôle Clermont-limagne............................... 15
Cardio Renal....................................................... 35
Cancer-bio-santé Cluster.................................. 16
Carthera.............................................................. 36
Cci International Grand Est............................... 16
Cea-leti............................................................... 36
SATT Conectus.................................................. 17
Cellprothera....................................................... 37
Eurobiomed....................................................... 17
Centaur Clinical................................................. 37
France Biotech................................................... 18
Cilcare SAS......................................................... 38
Genopole........................................................... 18
Ciloa SAS............................................................ 38
Id2santé.............................................................. 19
Cisbio.................................................................. 39
SATT IDF Innov.................................................. 19
Clean Cells......................................................... 39
Institut Imagine.................................................. 20
Clevexel Pharma................................................ 40
Invest In Lyon - Aderly....................................... 20
Crescentia Consulting....................................... 40
SATT Lutech....................................................... 21
Crossject............................................................. 41
Lyonbiopole....................................................... 21
Cynbiose............................................................. 41
Montpellier Méditerranée Métropole /
Cytoo.................................................................. 42
Montpellier, France Health Hub....................... 22
Dynacure............................................................ 42
Nutrition Health Longevity Cluster.................. 22
Endodiag............................................................ 43
SATT Ouest Valorisation................................... 23
Enterome Bioscience........................................ 43
SATT Sud-Est..................................................... 23
Enterosys............................................................ 44
Enyo Pharma...................................................... 44
COMPANIES Evotec................................................................. 45
4clinics................................................................ 25 Expernova.......................................................... 45
Acticor Biotech.................................................. 25 Eyevensys SAS................................................... 46
Affilogic.............................................................. 26 Fab'Entech......................................................... 46
Alaxia.................................................................. 26 Flashcell.............................................................. 47
Alira Health Sas.................................................. 27 Genochem.......................................................... 47
Alizé Pharma 3................................................... 27 Genoway............................................................ 48
Amylgen............................................................. 28 Gensight Biologics............................................ 48
Anagenesis Biotechnologies............................ 28 H-immune........................................................... 49
7EXHIBITORS LIST
Haliodx SAS....................................................... 49 Oxeltis................................................................. 64
Histalim SAS....................................................... 50 Pep-therapy........................................................ 64
Horama............................................................... 50 Phenocell............................................................ 65
Htl........................................................................ 51 Physiostim.......................................................... 65
Hybrigenics Services......................................... 51 Plant Advanced Technologies.......................... 66
Indicia Production.............................................. 52 Polyplus-transfection......................................... 66
Inflectis Bioscience............................................ 52 Rondol Industrie................................................ 67
Innopain.............................................................. 53 Sensorion............................................................ 67
Inovotion............................................................ 53 Signia Therapeutics SAS................................... 68
Inventiva............................................................. 54 Smartox Biotechnology..................................... 68
Iris Pharma.......................................................... 54 Soladis................................................................ 69
Keen Eye............................................................. 55 Synapcell............................................................ 69
Keosys................................................................. 55 Temisis................................................................ 70
Laboratoir Icare.................................................. 56 Theradiag........................................................... 70
Lxrepair SAS....................................................... 56 Theranexus......................................................... 71
Mabdesign......................................................... 57 Theranyx............................................................. 71
Manros Therapeutics......................................... 57 Theravectys........................................................ 72
Medday Pharmaceuticals.................................. 58 Transcure Bioservices........................................ 72
Medincell............................................................ 58 Txcell................................................................... 73
Nanobiotix......................................................... 59 Vaiomer SAS....................................................... 73
Neovacs.............................................................. 59 Valneva............................................................... 74
Neuroservice...................................................... 60 Vect-horus.......................................................... 74
Nextep................................................................ 60 Vibiosphen......................................................... 75
Nicox SA............................................................. 61 Virbac.................................................................. 75
Nosopharm........................................................ 61 Voisin Consulting Life Sciences........................ 76
Novadiscovery................................................... 62 Voxcan................................................................ 76
Olmix Group...................................................... 62 Yposkesi.............................................................. 77
Orphelia Pharma................................................ 63 Yslab................................................................... 77
Osivax................................................................. 63
8SPONSORS USA – BOSTON / JUNE 4 – 7, 2018
AXELIA AXELIA PARTNERS provides the support entrepreneurs
need to expand and succeed in the US. Our cross-Atlantic
PARTNERS business expertise enables foreign companies to set up
their US operations efficiently and manage them compliantly.
With a personalized approach to delivering comprehensive
business solutions and consulting services, Axelia Partners
has become the trusted partner of hundreds of companies
at every stage of their US venture.
Operations Setup | Accounting | Financial Control | Payroll |
HR Services | Talent Search | M&A advisory.
AXELIA PARTNERS
185 Alewife Brook Parkway #210
CAMBRIDGE MA 02138
USA
Ph.: +1 617 576 2005
Fax: +1 617 576 2001
Alexandra SUHAS
Partner
Ph.: +1 617 852 5333 Date of creation: 1989
asuhas@axeliapartners.com Number of employees: 35
Activity: Management Services and Consulting
Key-words: operations setup, accounting, financial control,
payroll, hr services, talent search, m&a
www.axeliapartners.com
BLUEREG Consultancy organization offering strategic scientific &
regulatory advice as well as hands-on solutions to life
PHARMA sciences companies from drug development right through
to authorisation and beyond.
CONSULTING Our expertise includes global and local regulatory, CMC,
clinical & non-clinical scientific writing and pharmacovigilance.
Through our France-based affiliate Pharma Blue, we partner
with Biotechs pharma companies developing late stages’
innovative therapies to provide them with integrated solutions
to accelerate the marketing of their products in EU Countries.
Through our European offices and qualified partners,
we can provide local in-country services in regulatory,
BLUEREG PHARMA pharmacovigilance & quality management services.
CONSULTING BlueReg is located in France, UK & USA.
1800 route des Crêtes
Les 2 Arcs Bât A
06560 VALBONNE SOPHIA
ANTIPOLIS
France
Date of creation: 10/04/11
Ph.: +33 (0)4 22 00 01 00
Number of employees: 55
Activity: Strategic regulatory advice and hands-on outsourcing
Franck AUVRAY solutions
VP General Manager Pharma Blue Key-words: Consultancy, Regulatory strategy, Regulatory
Cel.: +33 (0)6 87 60 88 59 Operations, scientific advice, Pharmacovigilance, Early
auvray.franck@blue-reg.com access, drug development, CMC, Scientific writing, lifecycle
management, EU, US
www.bluereg-group.com
10PACT AND PARTNERS PACT & PARTNERS is the life sciences expert recruiter that
you need!
- LIFE SCIENCES
RECRUITMENTS We are the next generation of headhunters, bringing you
faster results for better talents.
We have made thousands of successful recruitments in the
last 3 decades!
We are experts in International and Local recruitments in the
US, LatAm and Europe.
Looking to reinforce your teams or expand abroad? Our
international team is here to support you in your talent
development.
Pact & Partners has acquired proven experience in all Life
PACT AND PARTNERS - LIFE Sciences positions, from mid- to C-level recruitments.
SCIENCES RECRUITMENTS
50 Milk Street (16th Floor) Contact us today for a FREE QUOTE: https://pactandpartners.
02109 BOSTON com/contact-us/
USA
Olivier SAFIR
CEO Date of creation: 1987
Cel.: +33 (0)6 86 76 09 35 Number of employees: 53
osafir@pactpartners.com Activity: Recrutements
Therapeutic area: Tous
Key-words: E x pansion commerciale International,
Recrutements, Chasse de tete, Consulting, Experts,
Implantations,
www.pactandpartners.com
11PARTNERS USA – BOSTON / JUNE 4 – 7, 2018
ALSACE ALSACE BIOVALLEY is a French competitiveness cluster that
has the mission to federate, develop and promote health
BIOVALLEY players through innovation. The cluster actively participates
in developmental projects of the health sector and supports
its members in their R&D innovation approaches enabling
them to access high national and international added-value
expertise (regulatory, clinical studies ...). It also contributes to
the networking of its members and develops the ecosystem
visibility, in order to boost market access.
The priorities of the cluster are:
• Medicine: from development to production
• M edical Technologies: medical robotic s, imaging,
ALSACE BIOVALLEY implantable devices
550 boulevard Gonthier • e -Health: from prevention of pathologies to individual
D'andernach patient track.
67400 ILLKIRCH
France
Ph.: +33 (0)3 90 40 57 40
Fax: +33 (0)3 90 40 30 01
Guillaume FACCHI
Strategic Program Coordinator Date of creation: 1998
Ph.: +33 (0)3 90 40 30 02 Number of employees: 12
Cel.: +33 (0)6 77 97 67 39 Activity: pôle de compétitivité
guillaume.facchi@alsace-biovalley.com Key-words: cluster - biotechnology- therapeutic
innovations- e health
www.alsace-biovalley.com
SATT AQUITAINE - SATT AQUITAINE is the French Technology Transfer Office of
Bordeaux and Aquitaine area (France) academic laboratories,
AQUITAINE SCIENCE dedicated to the economic valuation of patents based
TRANSFERT on public research technologies. We help finance and
develop proofs of concepts and we license-out disruptive and
incremental innovations or promote creation of technological
start-ups.
We are highly specialized in healthcare and wellness projects.
Our portfolio addresses a large therapeutic area (oncology,
pulmonary diseases, dermatology ...) and encompasses a wide
range of technologies from drugs, diagnosis kits, medical
devices and software to Drug Delivery Systems and galenics.
Member of: Reseau Satt
SATT AQUITAINE - AQUITAINE
SCIENCE TRANSFERT
351 cours de La Libération
33405 TALENCE
France
Ph.: +33 (0)5 33 51 43 00
Jean-Luc CHAGNAUD Date of creation: JULY 2012
Healthcare Business Development Number of employees: 42
Manager Activity: TECHNOLOGY TRANSFER
Ph.: +33 (0)5 33 51 43 26 Therapeutic area: COPD - Scleroderma - Oncology -
Cel.: +33 (0)6 26 53 43 97 Regenerative medecine
jl.chagnaud@ast-innovations.com Key-words: Drug Delivery System - Galenics- Medical
Devices & Software - Drugs -
www.ast-innovations.com
13ASSISTANCE AP-HP (Greater Paris University Hospitals) is a European
world-renowned university hospital. Its 39 hospitals treat 8
PUBLIQUE – million people every year: in consultation, emergency, during
HÔPITAUX DE PARIS scheduled or home hospitalizations.
(AP-HP) The AP-HP provides a public health service for everyone, 24
hours a day. This mission is a duty as well as a great source of
pride. AP-HP is the leading employer in the Greater Paris area:
100.000 staff members – doctors, researchers, paramedical
staff, administrative personnel and workers – work there.
The Clinical Research and Innovation Department (DRCI) of
AP-HP coordinates 2700 clinical trials, among which around
Member of: Medicen 800 are sponsored by AP-HP with more than 26 000 patients
enrolled. We also provide you with tech transfer opportunities,
ASSISTANCE PUBLIQUE – partnerships and research collaborations
HÔPITAUX DE PARIS (AP-HP)
3 avenue Victoria
75004 PARIS
France
Benoit LABARTHE
Head of the Office of Tech Transfer
Cel.: +33 (0)6 32 54 26 45
benoit.labarthe@aphp.fr
Number of employees: 95 000
www.aphp.fr
ATLANPOLE ATLANPOLE BIOTHERAPIES is a international cluster in
west of France with more than 170 business members. ABT
BIOTHERAPIES is active leader of a vibrant ecosystem, supporting start-ups
and innovative SMEs in biotherapy.
With focus on immunotherapy, radiopharmaceuticals,
regenerative medicine and innovative technologies for
biotherapies, ABT participates in design of Medicine of
Tomorrow. ABT coordinates the work of laboratories,
companies and platforms for a public-private complete,
relevant and competitive solution, on the bio-medicine value
chain from target discovery to clinical evaluation.
Member of: Atlanple
Biotherapies Our companies have developed products and technologies,
which on one hand address American market and on the other
ATLANPOLE BIOTHERAPIES hand can offer interesting opportunities for collaboration.
Château de La Chantrerie
95 route de Gachet
44307 NANTES
France
Ph.: +33 (0)2 40 25 13 99 Date of creation: 2005
Fax: +33 (0)2 40 25 10 88 Number of employees: 10
Activity: Biotherapy Cluster
Florence HALLOUIN Therapeutic area: Oncology, Transplantation, Immune
Deputy Director diseases, Orphan diseases ...
Ph.: +33 (0)2 40 25 23 91 Key-words: Immunotherapy, Regenerative Medicine,
Cel.: +33 (0)6 82 88 42 83 Radiopharmaceuticals, Technology for Biotherapies,
hallouin@atlanpole.fr Biotechnology, Bioregion, Radiopharma, Transplantation,
Cluster, Business development
www.atlanpolebiotherapies.fr
14SATT AXLR AXLR is a technology transfer acceleration company. Our
specialty is helping innovative projects derived from academic
research reach maturity and commercialization. We work
with the main public-sector research laboratories in France's
Mediterranean area in Occitanie, one of the most dynamic
locations in Europe, with over 200 laboratories and some
12,000 researchers.
Member of: Réseau Satt
SATT AXLR
950 rue Saint Priest
34090 MONTPELLIER
France
Ph.: +33 (0)4 48 19 30 01
Marc CRITON
Business Developer
Ph.: +33 (0)4 48 19 30 14
Cel.: +33 (0)6 50 97 34 49
marc.criton@axlr.com Date of creation: 2012
Number of employees: 35
Activity: technology tranfer company
Therapeutic area: all fields
www.axlr.com
BIOPÔLE The BIOPÔLE CLERMONT-LIMAGNE was one of the first
European technology parks fully dedicated to hosting and
CLERMONT- supporting biotechnology businesses.
In addition to 20 000 m2 of laboratory space devoted to
LIMAGNE biotechnology activities, it offers bio entrepreneurs an
extensive range of tools aimed at enhancing business creation
and development: creation support, networks and funding.
It is also an interactive platform for professionals of the
life sciences sector, encouraging collaborative networking
bet ween companies, research centers, professional
associations, science parks and economic development
organizations.
Member of: Lyonbiopôle Over 50 businesses and organizations are currently developing
BIOPÔLE CLERMONT-LIMAGNE their activities on the Biopôle.
2 rue Michel Renaud Biopôle is a member of the Arbios Network.
63360 SAINT-BEAUZIRE
France
Date of creation: 1995
Ph.: +33 (0)4 73 64 43 43
Number of employees: 1400
Activity: Biopark
Nathalie NIGON Therapeutic area: nutrition, anti-infectives, drug delivery,
EHS Manager/Companies Welcome molecular diagnostics, peptides, proteins, analgesics, vaccines,
Ph.: +33 (0)4 73 33 74 27 nervous system, digestive system, oncology, probiotics
nathalie.nigon@biopole-clermont. Key-words: anti-infec tives, drug deliver y, molecular
com diagnostics, peptides, proteins, analgesics, vaccines, nervous
system, digestive system, oncology, probiotics, biocluster,
biopark, hosting, economic development, biotechnology,
networks, biopole
www.biopole-clermont.com
15CANCER-BIO- The CANCER-BIO-SANTÉ CLUSTER is the only French cluster
wholly dedicated to innovation in the field of cancer and
SANTÉ CLUSTER healthy ageing, from biotechnology to medical devices. The
Cancer-Bio-Santé Cluster is based on the Toulouse Oncopole
campus, located in the heart of Toulouse.
Our principal missions are to foster innovation in oncology
and healthy ageing:
• To promote interdisciplinarity through scientific meetings
between clinicians, researchers and industries and to initiate
collaborative R&D projects, that can benefit from public
Member of: Cancer-bio-santé grant support
Cluster • To support company member growth
CANCER-BIO-SANTÉ CLUSTER • To ensure the follow-up of accredited projects
5 avenue Irène Joliot-Curie • To improve access to private funding
31100 TOULOUSE
• To develop relevant international networks that can foster
France
partnerships and collaborative projects for its members.
Fabienne DE TONI-COSTES
Biotechnologies and Oncology
Project Manager
Ph.: +33 (0)5 34 25 50 42
Cel.: +33 (0)6 45 70 36 38
f.detonicostes@cancerbiosante.fr Date of creation: 2005
Number of employees: 7
Activity: Health cluster
Key-words: Oncology and healthy aging
cancerbiosante.fr
CCI CCI INTERNATIONAL GRAND EST is the international
department of the Chambers of Commerce and Industry of
INTERNATIONAL the "Grand Est" region.
GRAND EST A team of expert advisors supports companies at every stage
of their international development.
Our missions:
• provide information (market prospects, regulation, export
diagnosis), advice and technical training
• d etect and monitor SMEs with strong growth potential,
support them over the long term with a tailor-made offer
to grow on targeted markets
• organize collective or individual prospecting actions.
CCI INTERNATIONAL GRAND EST
10 place Gutenberg CS20003 As exportation gateway and strategic partner of the
67085 STRASBOURG CEDEX
Regional Council, CCI International Grand Est develops
synergies between companies and the partners of the
France
internationalization support program, in close collaboration
Ph.: +33 (0)3 88 76 42 12
with the competitiveness and business clusters.
Valérie MOTTL
International Trade Advisor
Ph.: +33 (0)3 83 85 54 78 Number of employees: 38
Cel.: +33 (0)6 42 24 60 83 Ac tivity: Supporting companies in their international
v.mottl@grandest.cci.fr development
Key-words: International development - Export Strategy
- Individual support - Prospecting missions - Trade fairs -
www.cci-international- International regulation
grandest.com
16SATT CONECTUS Alsace is a Tech Transfer Company managing all
IP and tech transfer activities from academic labs in Alsace
CONECTUS (over 9000 scientists).
Conectus operates a 42M€ PoC fund to develop opportunities
at a higher level of readiness. We manage IP portfolios from the
initial detection and protection strategy up to licensing deals.
We analyze over 120 invention disclosure/year (50% in health
and life science field) and invest 5M€/year in POC programs.
Conectus is your exclusive business partner for all academic
innovation acquisition in Alsace, and can provide you with
a privileged access to a unique and highly advanced know-
Member of: Réseau Satt hows, skills and facilities.
SATT CONECTUS Our team has proven skills in building effective B2B
650 boulevard Gonthier relationships with pharmas, biotechs, start-ups and investors
d'Andernach and exhibits a strong deal-making track record.
67400 ILLKIRCH
France
Ph.: +33 (0)3 68 41 12 60
Fax: +33 (0)3 68 41 12 70
Vincent BISCHOFF Date of creation: 2012
Business Developper Number of employees: 34
Cel.: +33 (0)6 09 79 06 13 Activity: Technology Transfer & collaborative research
vincent.bischoff@satt.conectus.fr Therapeutic area: All therapeutic fields
Key-words: Technology transfer, proof-of-concept,
preclinical
www.conectus.fr
EUROBIOMED EUROBIOMED is the catalyst of the health sector in Southern
France.
EUROBIOMED provides resources and offers solutions for
businesses and research organisations. EUROBIOMED helps
them innovate, finance, develop and achieve their strategic
and business objectives to ultimately improve life through
innovations in health.
Founded in 2005 by regional stakeholders, EUROBIOMED
tops European rankings in all stages of innovation: education,
basic research, translational and clinical research, technological
innovation centers, start-ups and Industrial success stories.
Member of: Eurobiomed Together, the + 270 EUROBIOMED members are a driving
EUROBIOMED force in regional development and a source of solutions for
8 rue Sainte Barbe millions of patients coping with serious conditions such as
13001 MARSEILLE cancer, chronic inflammatory disease, infectious diseases ...
France
Ph.: +33 (0)4 91 13 74 65
Camille SUMNER Date of creation: 29/11/05
International Project Manager Number of employees: 12
Cel.: +33 (0)7 63 02 00 34 Activity: Health Cluster
camille.sumner@eurobiomed.org Therapeutic area: Cancer, Immunology, Infectiology,
Neurology, Diagnosis, Rare diseases, e health
Key-words: health cluster; Fundraising, Accelerator,
Innovation, R&D project, Networking, access to european
market
www.eurobiomed.org
17FRANCE Created in 1997, FRANCE BIOTECH is a French non-for-profit
organization that brings together the country’s leading
BIOTECH innovative health companies and their expert partners. France
Biotech's primary mission is to support the development of this
industry in France, by improving the tax, legal, regulatory and
managerial environment in which these companies operate and
by advocating for their recognition as a leading-edge industry.
France Biotech also aims to turn French innovative health
technologies into world leaders. The organization, which
championed the creation of the French Young Innovative
Company (JEI) status in 2004, develops a wide range of
actions intended to set the innovative health sector on an
independent and high-performance course.
FRANCE BIOTECH
3-5 impasse Reille
75014 PARIS
France
Ph.: +33 (0)1 56 58 10 70
Sophie VILLEDIEU
Member Services Manager
Ph.: +33 (0)1 88 32 00 46
Cel.: +33 (0)6 64 27 32 25
sophie.villedieu@france-biotech.org Date of creation: 1998
Number of employees: 4
Activity: Association d'entrepreneurs Health Tech
Key-words: Healthtech Entrepreneurs
www.france-biotech.fr
GENOPOLE GENOPOLE is France's leading biocluster and a key player
in the field of biotherapies and biotechnology. Strategically
positioned in the Paris Region, it benefits from world-class
hospitals, pharma and biotech companies and top-ranked
international business schools.
Genopole’s highly diversified set of corporate members
includes innovative drug discovery firms, diagnostics
manufacturers and scientific & medical instrumentation
suppliers, together with businesses in the environmental and
agricultural sectors.
Genopole’s goal is to promote research excellence in the life
Member of: Genopole sciences and to catalyze the creation of biotech companies, in
order to keep France up with the leaders in a highly competitive
GENOPOLE international scientific and industrial environment.
5 rue Henri Desbruères
91000 EVRY
France
Ph.: +33 (0)1 60 87 83 00
Fax: +33 (0)1 60 87 83 01
Jean-Marc GROGNET
Chief Executive
Ph.: +33 (0)1 60 87 83 24
jean-marc.grognet@genopole.fr Date of creation: 1998
Number of employees: 46
Activity: biocluster
Key-words: Development / accompaniment / incubation /
www.genopole.fr
18ID2SANTÉ ID2SANTÉ is the Atlanpole Biotherapies competitive cluster
relay in Bretagne. In close contact with researchers and
companies from the health sector, we help to develop
innovative health projects.
We are able to connect you with regional key players and
experts in:
• M edical technologies with diagnostic and therapeutic
purposes (medical devices, computer assisted surgery,
imaging), living labs in ambient assisted living
• E-health, telemedicine, personal medical e-file, big data
processing
Member of: Atlanpole
Biotherapies • New therapeutic solutions with biotech/pharmaceuticals
(molecules, biomarkers, genetics, preclinical and clinical
ID2SANTÉ research, biological resource centers, marine compounds
2 avenue du Pr Léon Bernard - sourcing…)
CS34317
35043 RENNES CEDEX
• Prevention and nutrition (development of ingredients,
France
food for medical purposes, clinicaresearch in nutrition and
metabolism, toxicology).
Ph.: +33 (0)2 23 23 45 81
Fax: +33 (0)2 23 23 45 86 Date of creation: 1985
Number of employees: 9
Jocelyne LE SEYEC Activity: Technology innovation centre in Western France
Project manager Therapeutic area: Medical devices, imaging, health
Ph.: +33 (0)2 23 23 45 85 technologies, e-health, biotechnology, drug development,
Cel.: +33 (0)6 76 23 53 22 new therapies, nutrition
jocelyne.leseyec@id2sante.fr Key-words: Human health, Biotherapies, Biotech, Medtech,
e-Health, Innovation, Technology transfer
www.id2sante.fr
SATT IDF INNOV Accelerating Technology Transfer companies (SATT - Société
d'Accélération de Transfert Technologique) are private
companies founded under the French "Investments for
the Future" program, as an interface between academic
laboratories and innovative businesses. IDF Innov stakeholders
are mainly world-class research centers based in Paris Region.
IDF Innov focuses particularly on transforming inventins into
innovations that can be used to develop products and services
that meet your industrial and commercial needs.
We work alongside academic researchers to build, finance and
support the development of their inventions (proof of concept),
Member of: Réseau Satt working closely, even in partnership, with manufacturers and
investors.
SATT IDF INNOV
37 rue de Lyon
75012 PARIS
France
Ph.: +33 (0)1 40 23 21 50
Noémie PELLEGRIN
Head of Business Development
Lifescience
Ph.: +33 (0)1 80 06 80 05 Date of creation: 2012
Cel.: +33 (0)7 61 86 77 56 Number of employees: 52
npn@idfinnov.com Activity: Transfert de technologies
Therapeutic area: oncology, auto-immune disease,
neurology, infectious disease
www.idfinnov.com
19INSTITUT IMAGINE INSTITUTE is a University Hospital Institute wholly
dedicated to translational research in genetic and rare
IMAGINE diseases, at the crossroads between academic research,
hospital care, patients groups & foundations, and industry.
Our activities rely on a strong expertise in genetic diseases,
as well as preclinical, clinical and technological resources
inherited from a long tradition of research and care at Necker
Children’s Hospital.
THERAPEUTIC AREAS: immunology, hematology, infectiology,
nephrology, neurosciences, cardiology, developmental
diseases, etc.
ACTIVITIES: PoC studies, drug development or repurposing
INSTITUT IMAGINE projects, innovative therapeutic and diagnostic approaches,
24 boulevard du Montparnasse etc. through basic research collaborations, out-licensing,
75015 PARIS spin-off creation...
France PARTNERS: Pharmaceutical companies, biotech, and VC firms.
Ph.: +33 (0)1 42 75 42 00
Fax: +33 (0)1 42 75 42 23
Romain MARLANGE
Head of Innovation & Technology Date of creation: 2011
Transfer Department Number of employees: >500
Ph.: +33 (0)1 42 75 43 63 Activity: Translational research
Cel.: +33 (0)6 25 04 20 71 Therapeutic area: Rare diseases
romain.marlange@institutimagine.org Key-words: Rare diseases, genetic diseases, pediatric,
translational research
www.institutimagine.org/en/
INVEST IN LYON INVEST IN LYON - ADERLY (economic development agency
of Lyon) offers free of charge services to encourage inward
- ADERLY investment in Lyon, FRANCE. Our role is to advice and guide
on every aspect the companies that wish to develop their
business in our region.
The economic ecosystem in Lyon is extremely rich in health
and life sciences oriented companies. Join this dynamic
network by investing in your proximity with your strategic
clients and partners.
ADERLY: Lyon Area Economic Development Agency - www.investinlyon.com
INVEST IN LYON - ADERLY
Place de La Bourse
69002 LYON
France
Ph.: +33 (0)4 72 40 58 31
Nathalie LAURENT
Senior Inward Investment Manager
Ph.: +33 (0)4 72 40 59 25
Cel.: +33 (0)6 17 81 74 28 Date of creation: 1974
nlaurent@investinlyon.com Number of employees: 43
Activity: Economic development agency of Lyon
Key-words: Foreign direct investment; Biotech; CMO; CRO;
Diagnostic; Medical Devices; Pharma
www.investinlyon.com
20SATT LUTECH SATT LUTECH is a private technology transfer company with
exclusive right to source, protect, develop and commercialize
scientific findings and technologies stemming from the
research laboratories of its partners and shareholders.
Lutech aims at facilitating the transfer of early stage innovations
with real potential to improve life quality, transform industries
and create tremendous social & economic value by investing
in the development of convincing proof of concept and
prototypes.
Lutech is partnering with operating companies and investors
at any development stage through co-development programs,
Member of: Reseau Satt licensing or startup creation.
SATT LUTECH
4 rue de Ventadour
75001 PARIS
France
Michael BAKRIA
Business Developer
Cel.: +33 (0)7 81 44 26 37
michael.bakria@sattlutech.com Date of creation: 2012
Number of employees: 42
Activity: Technology Transfer
Therapeutic area: All
Key-words: Technology Transfer, Biotech, Diagnostic,
Therapeutics, Regenerative Medicine
www.sattlutech.com
LYONBIOPOLE LYONBIOPOLE, the gateway to life sciences’ innovation in
the Auvergne-Rhône-Alpes Region, unites the industry and
enhances strategic collaboration by providing full support for
economic development, innovation and internationalization.
The cluster missions are:
1) to promote the emergence of innovative R&D collaborative
projects
2) to support SMEs to set up strategic partnerships and to
access private investors, expertise and training
Auvergne - R hône - Al pes
3) to foster SMEs' Internationalization
Member of: Lyonbiopole 4) to give access to GLP / GMP dedicated facilities.
LYONBIOPOLE In 2017, Lyonbiopole represented a community of 208
321 avenue Jean Jaures members: 6 founding members (Sanofi Pasteur, bioMérieux,
69007 LYON
Boehringer Ingelheim Animal Health, Becton Dickinson, CEA
and Fondation Merieux), 188 innovative companies and 14
France
Research & clinical Centers.
Kevin ROMANI
Director SME Development
Ph.: +33 (0)4 72 76 53 30
kevin.romani@lyonbiopole.com
Date of creation: 2005
Number of employees: 20
Activity: Healthcare Cluster
Therapeutic area: Oncology, Infec tious Diseases,
Immunology, Neurology, Regenerative Medicine
lyonbiopole.com
21MONTPELLIER Montpellier is a territory for research and innovation, with
MÉDITERRANÉE MÉTROPOLE strong entrepreneurial vitality and a long tradition in health,
/ MONTPELLIER, FRANCE now set on medicine of the future.
HEALTH HUB The "Montpellier Capital Santé, France Health Hub" project
is leveraging the effervescent, creative spirit of a dynamic
ecosystem to take on many key challenges for tomorrow’s
health care.
A fertilizing environment: presence of leading French research
centers, the successful University of Montpellier, a widely
recognized university hospital (CHU), the Eurobiomed
competitiveness cluster, a network of more than 200 companies
Member of: Eurobiomed and promising startups expanding into international markets,
a site dedicated to companies (Biopôle Euromédecine), the
MONTPELLIER MÉDITERRANÉE BIC startup incubator (ranked 2nd in UBI Global 2018), and
MÉTROPOLE / MONTPELLIER,
the French Tech HealthTech thematic network.
FRANCE HEALTH HUB
50 place Zeus CS39556
34961 MONTPELLIER CEDEX 2
France
Ph.: +33 (0)4 67 13 69 32
Trias ASTERIOU
Health Project Manager
Ph.: +33 (0)4 67 13 61 20
t.asteriou@montpellier3m.fr Key-words: Montpellier, Innovation, Health, Life Sciences,
Healthtech, biotech, medtech, diagnostics, e-health,
Biopark, french tech
www.invest-in-montpellier.com
NUTRITION HEALTH THE NUTRITION HEALTH LONGEVITY (NHL) cluster is a
dynamic network focusing on the main issues at the crossroads
LONGEVITY of health, biotechnology and nutrition. The NHL Cluster aims
CLUSTER to federate academia and industry partners around R&D
projects, which lead to innovative products in the fields of
nutrition and health.
The NHL Cluster’s activity is centred around the prevention
and treatment of life-style related diseases, such as metabolic
and cardiovascular pathologies, neurodegenerative and
inflammatory bowel diseases. Its objective is to gather and
support players from the health and food sectors in the design,
the development and financing of their future products and
processes.
NUTRITION HEALTH www.nhl-cluster.com
LONGEVITY CLUSTER
Parc Eurasanté Ouest @PoleNSL
310 avenue Eugène Avinée
59210 LOOS (LILLE METROPOLE)
France
Date of creation: 2005
Ph.: +33 (0)3 28 55 50 14 Number of employees: 10
Activity: Cluster
Etienne VERVAECKE Therapeutic area: life-style related diseases, metabolic,
General Manager cardiovascular, neurodegenerative and inflammatory bowel
Ph.: +33 (0)3 28 55 90 65 diseases
Cel.: +33 (0)6 770 772 37 Key-words: cluster, innovation, network, health, biotechnology,
evervaecke@pole-nsl.org nutrition, longevity, academia-industry partners, R&D
projects, financing
www.nhl-cluster.com
22SATT OUEST OUEST VALORISATION, a french Office of Technology Transfer
(OTT), propose to companies attractive innovation means
VALORISATION from the public research.
Ouest Valorisation’s team simplifies the access of the
companies to research laboratories in order to develop good
collaborative projects or to get access to high professional
skills and high level scientifical equipment.
Founded in July 2012, the company is responsible for the
maturation, licensing and the transfer of technologies of six
french major campuses to the commercial sector.
Ouest Valorisation SAS protects and manages the intellectual
Member of: Réseau Satt property developed by more than 7000 full time equivalent
SATT OUEST VALORISATION faculty members, researchers, and technologists from
14 C rue du Pâtis Tatelin - universities, engineering schools hospitals and national
Métropolis 2 - CS80804 research institutions loccaly present in academic reserch labs.
35708 RENNES
France
Ph.: +33 (0)2 99 87 56 01
Hervé LE DEIT
Business Developer Date of creation: 7/20/2012
Ph.: +33 (0)2 98 01 62 71 Number of employees: 90
Cel.: +33 (0)6 18 70 35 04 Activity: technology transfert office
herve.le-deit@ouest-valorisation.fr Therapeutic area: oncology, antibiotic, Ischemic Acute Stroke
Key-words: oncology, melanoma, antibiotic, biomarker,
stroke, probiotic, cosmetic
www.ouest-valorisation.fr
SATT SUD-EST SATT SUD-EST, the “Technology Transfer accelerator” is a
key player in regional economic development associated with
innovation. Its core business, technology transfer, consists of
protecting, maturing and licensing the Results of research
from public laboratories in the PACA and Corsica Regions.
Its goal is to help companies acquire reliable technologies
that are better suited to the industrial challenges they face.
SATT Sud-Est is a simplified joint-stock company with a
capital of €1 million. Its shareholders include the Universities
of Aix-Marseille, Nice, Toulon, Avignon, Corsica, Centrale
Marseille, CNRS, Inserm and CDC. Project financed with the
support of the European Union with the European Regional
Member of : Réseau SATT Development Fund.
SATT SUD-EST
8 rue Sainte Barbe - CS10422
13205 MARSEILLE CEDEX 01
France
Ph.: +33 (0)4 91 91 91 20
Rémi PICARD Date of creation: January, 2012
Marketing Officer, Health & Life Number of employees: 42
Sciences Activity: Tech Transfer
Cel.: +33 (0)7 81 67 45 73 Therapeutic area: Oncology, Immuno-Oncology, Inflammatory
remi.picard@sattse.com diseases, Cardiovascular & metabolic diseases, Neurosciences,
Infectious diseases, Rare diseases
Key-words: Therapeutics, In Vitro Diagnostics, Medical
Devices, Technology Transfer, Licensing
www.sattse.com
23COMPANIES USA – BOSTON / JUNE 4 – 7, 2018
4CLINICS 4CLINICS provides services in clinical operations, data
management, biostatistics, medical writing, and regulatory
affairs with a focus on vaccines, immunotherapeutics, cell &
gene therapies and medical devices.
• Full services for Phase I-III, observational, PoC, feasibility,
safety, CE mark and PMCF studies from synopsis to report
including regulatory and operational support
• Stand-alone services in clinical operations, data management,
biostatistics, medical writing or regulatory affairs
• Customized services and consultancy from preclinical to
first-in-man including medical, regulatory, statistical and
Member of: Medicen feasibility expertise.
4CLINICS 4Clinics has offices in Paris, Brussels, Boston and Kenitra and
18-26 rue Goubet worldwide coverage.
75017 PARIS - France
Cel.: +33 (0)6 22 84 11 54
Mehdi CHELBI
Director Business Development
Ph.: +33 (0) 6 22 84 11 54 Number of employees: 65
mchelbi@4clinics.com Activity: Clinical Obesrvational and Epidemiological Studies
Therapeutic area: Infectious Diseases (Vaccines) Oncology
Local representative: 4CLINICS Immunology related diseases Rare Diseases Medical Devices
Cic One Broadway 14th Floor Key-words: Clinical Operations Clinical Studies Biostatistics
MA 02142 Cambridge -USA Medical Writing Vaccines Cell and Gene Therapies
Immunotherapeutics Medical Devices
www.4clinics.com
ACTICOR ACTICOR BIOTECH (http://acticor-biotech.com/en/), is a
French clinical stage bio-pharma company founded late 2013,
BIOTECH which develops an innovative treatment for acute ischemic
strokes (AIS), representing currently more than 80% of the
global stroke market.
Despite the clear unmet medical need, no new drug has been
approved in the last decade, mainly due to the bleeding risk
every new thrombolytic or antiplatelet agent carries.
Acticor has developed a new approach targeting the
glycoprotein VI, thereby creating a paradigm shift of a new
class of antithrombotic drugs without any bleeding risk.
Member of: Medicen ACT-017, Acticor’s lead compound, is a human fragment of
Monoclonal Antibody proven to be efficient and very safe in
ACTICOR BIOTECH various preclinical models (including primates). It is entering
Hopital Bichat - Inserm U1148 Phase 2a in patients in Q3-2018.
46 rue Henri Huchard
75018 PARIS
France
Cel.: +33 (0)6 76 23 38 13
Gilles AVENARD
CEO
Date of creation: 2013
Cel.: +33 (0)6 09 16 68 50
Number of employees: 8
gilles.avenard@acticor-biotech.com
Activity: Biotechnology - Drug Development
Therapeutic area: Cardiovascular - Stroke - Acute Thrombosis
Key-words: Stroke - MoAb - Platelet glycoprotein 6
www.acticor-biotech.com
25AFFILOGIC AFFILOGIC is a private biotech company discovering and
developing Nanofitins as biotherapeutics.
Nanofitins are currently developed (i) as API, for inhibition of
inflammatory pathways or recruitment of immune cells (ii) for
targeting of Specific receptors in combination with a third-
party molecule such as antibodies, for imaging or ADC-like
strategy and (iii) for cellular uptake, to trigger PPI in cancer cells.
Nanofitins are easily combined with each other by simple, rapid
and proven methods to design an ideal targeted molecule.
We have a partnership-based business model as we
Member of: Atlanpole generate Nanofitins for our partners on a target by target
Biothérapies basis. Nanofitin-based biotherapeutics are currently being
developed in collaboration with Takeda Pharmaceutical, Sanofi
AFFILOGIC and other undisclosed pharmaceutical companies.
21 rue La Noue Bras de Fer
44200 NANTES
France
Ph.: +33 (0)2 40 35 49 18
Nadège PREL
Director, Marketing & Business
Development Date of creation: February 2010
Ph.: +33 (0)2 40 35 49 18 Number of employees: 16
nadege@affilogic.com Activity: Biotechnologies, R&D
Therapeutic area: Nanofitin-based biotherapeutics
Key-words: Non-injec table targeted therapies -
Multispecific biotherapeutics
www.affilogic.com
ALAXIA AL A XIA and its par tner Stragen develop innovative
therapeutics ALX-009 and STR-324.
ALX-009 is a first-in-class antimicrobial wide spectrum product
targeting to kills bacteria including antibiotic resistant strains
and to compensate deficient innate lung defense system
in Cystic Fibrosis. Other than the killing properties, the
potential of ALX-009 resides in its particular mode of action
not generating resistance. Clinical trial with CF patients is
currently ongoing.
STR-324 is a first-in-class non-opioid painkiller with a safe,
non-addictive and innovative mode of action DENKI based for
Member of: Lyonbiopole various pain indications including neuropathic pain. Clinical
trial is currently ongoing.
ALAXIA
60 avenue Rockefeller
Batiment Adenine
69008 LYON
France
Ph.: +33 (0)4 37 53 26 37
Date of creation: 2008
Philippe BORDEAU Number of employees: 8
VP Innovation & Business Activity: Therapeutics
Development Therapeutic area: Antimicrobials
Cel.: +33 (0)6 08 52 26 31 Key-words: New antimicrobials, antibiotics, orphan drug,
philippe.bordeau@bioalaxia.eu Cystic Fibrosis, first in class, Lung infection, Unmet Medical
Needs, resistance, rare disease, biofilm, respiratory, pain,
pain killer, non opioid, DENKI, neuropathic pain, new MoA
www.alaxia-pharma.eu
26ALIRA HEALTH ALIRA HEALTH is an international integrated advisory firm
providing discovery services, regulatory and clinical strategy,
SAS clinical development (CRO), market access and management
consulting as well as strategy execution support (HTA, M&A,
BD&L and fundraise).
Our strategists, bankers, doctors and scientists collaborate
to fully understand every aspect of healthcare.
We provide our clients with a continuum of support to achieve
success at any and every point in their business lifecycle.
Our expertise extends beyond the walls of convention and
Member of: Alira Health Group throughout every life science and healthcare sector. With Alira
Holdings LLC Health, you get a partner with broad market knowledge and
ALIRA HEALTH SAS expertise in strategy, execution and innovation that you need
31 rue de Monceau to accelerate your interests.
75008 PARIS
France
Ph.: +33 (0)1 44 54 96 23
Fax: +33 (0)9 72 58 03 30
William HARIRI
Director, Business Development
and Strategy Consulting Date of creation: 1999
Ph.: +44 (0)7 46 03 30 981 Number of employees: 100+
william.hariri@alirahealth.com Activity: Advisory in healthcare
Key-words: regulatory, clinical development, market access,
assessment, strategy, CRO, discovery, fundraise, M&A
www.alirahealth.com
ALIZÉ PHARMA ALIZÉ PHARMA 3 is focused on developing innovative
therapeutics for rare diseases.
3 Our first asset is AZP-3404, a short stabilized peptide derived
from IGFBP-2, a physiological protein that has been shown
to regulate bone, fat and glucose metabolism. On bone, it
is a key regulator of osteoblasts differentiation. AZP-3404
is at the preclinical stage for the treatment of osteogenesis
imperfecta, a rare bone disease, and has the potential to also
address unmet clinical needs in additional metabolic and
musculoskeletal indications.
Our strategy is to acquire additional programs to build a
Member of: Lyonbiopole leading biopharma in rare diseases with both European and
US presence to support global developments.
ALIZÉ PHARMA 3
15 chemin du Saquin
69130 ECULLY
France
Ph.: +33 (0)4 72 18 94 28
Fax: +33(0)4 72 18 09 29
Thierry ABRIBAT
President & CEO Date of creation: 2014
Ph.: +33 (0)4 72 18 94 28 Number of employees: 4
tabribat@alz-pharma.com Activity: Development of biopharmaceuticals in rare diseases
Therapeutic area: Rare metabolic and musculoskeletal diseases
Key-words: bone, osteogenesis imperfecta, endocrine,
musculoskeletal, rare disease, orphan
www.alz-pharma.com
27AMYLGEN AMYLGEN is a privately owned contract research organization
(CRO) offering a unique combination of validated in vivo
models and a full range of biochemical and morphological
testing allowing fast and predictive screening of the effects
of drugs and nutraceuticals on brain health.
We propose a panel of in vivo rodent models for a variety
of CNS disorders like depression, schizophrenia, anxiety
and more particularly neurodegenerative diseases like
Alzheimer. We also propose models allowing to test drugs or
nutraceuticals on aging brain (senescence accelerated mice
(SAM), D-Gal accelerated aging, normal aged mice).
Member of: Eurobiomed, Nsl
AMYLGEN
2196 boulevard de La Lironde
34980
France
Vanessa VILLARD
CEO
Ph.: +61 (0)4 97 45 66 55
vanessa.villard@amylgen.com Date of creation: 2009
Number of employees: 7
Activity: Pre-clinical CRO
Therapeutic area: Neurosciences
Key-words: Alzheimer, memory, behavior, biology, drug,
nutraceutic, efficacy, non-clinical
www.amylgen.com
ANAGENESIS ANAGENESIS BIOTECHNOLOGIES is a preclinical-stage stem
cell-based company focused on novel treatments for genetic
BIOTECHNOLOGIES and age-related muscles diseases with unmet medical needs.
Its unique propietary technology, allows to produce muscle
cells from stem cells through production of paraxial mesoderm
multipotent cells which are shared precursors of skeletal
muscle, ribs, vertebrae, dermis, endothelium & brown fat.
Pre-clinical POC has been obtained for muscular diseases
both with cell therapy & small molecules.
The cell therapy approach is now the focus of the newly formed
US-based subsidiary, Anagenesis Biotherapies. Anagenesis
Member of: Alsace Biovalley is seeking corporate partnerships and investors.
ANAGENESIS BIOTECHNOLOGIES
650 boulevard Gonthier D'andernach,
Parc D'innovation
67400 ILLKIRCH GRAFFENSTADEN
France
Ph.: +33 (0)3 88 43 10 08
Fax: +33 (0)3 88 43 10 08
Date of creation: avr.-11
Jean-Yves BONNEFOY Number of employees: 10
President & CEO Activity: Recherhe et développement en Biotechnologies
Ph.: +33 (0)3 88 43 10 08 Therapeutic area: Muscular Diseases
Ph.: +33 (0)6 20 88 50 92 Key-words: Renenerative Medicine - Stem Cells - Ophan
jybonnefoy@anagenesis-biotech.com diseases - DMD - Muscular diseases - Sarcopenia - Cachexia
www.anagenesis-biotech.com
28ANS BIOTECH ANS BIOTECH, a preclinical CRO dedicated to the in vivo
pharmacology of pain, offers a unique combination of
exceptional expertise in the fundamentals of pain pharmacology
and a proven record of R&D program management for the
new and innovative analgesics of its clients.
Our mission is to support the drug discovery and development
efforts of companies involved in human and animal health,
food and nutrition, by offering a broad range of consulting
services and a growing list of clinically relevant disease and
efficacy models.
Member of: Biopôle Clermont As a close Pharma and Biotech partner, we commit to providing
Limagne - Lyonbiopole cost-effective preclinical pharmacology services performed
to the highest ethical and quality standards. Our customized
ANS BIOTECH scientific studies can help to establish proof of concept &
20 - 22 rue Henri Et Gilberte Goudier mechanism of action for drug candidates.
63200 RIOM
France
Ph.: +33 (0)9 70 75 85 00
François CAUSSADE
CEO Date of creation: 2006
Ph.: +33 (0)9 70 75 85 03 Number of employees: 13
Cel.: +33 (0)6 80 17 03 50 Activity: contract research organization
francois.caussade@ans-biotech.com Therapeutic area: pain
Key-words: pain, hyperalgesia, allodynia, neuropathy,
irritable bowel syndrome, analgesia, analgesics, in vivo
pharmacology
www.ans-biotech.com
APTYS APTYS develops innovative products based of its expertise
in formulation.
PHARMACEUTICALS We deliver a ready to use package (formula and manufacturing
process, validated analytical methods and stability data).
Our offer: custom-made formulations; analytical development
and validation; quality control and ICH stability; in vivo/in
vitro assessments.
Our skills: topical and transdermal delivery, peptide delivery,
transmucosal delivery.
Track record: new transdermal gel of testosterone (phase
III); generic of inhaled product (market); injectable depot of
Member of: Lyonbiopole a peptide (pre clinic); generic of injectable buccal anesthetic
APTYS PHARMACEUTICALS (industrialization); buccal solution for trans-mucosal delivery
Biopole Clermont-limagne (phase I); oral combo dosage form (Phase III).
63360 SAINT-BEAUZIRE Quality: APTYS is ISO9001-2015 certified and holds GMP
France license from the French Agency.
Ph.: +33 (0)4 73 67 06 70
Fax: +33 (0)4 73 67 06 87
François BOUTIGNON
President and CEO Date of creation: 11/07/02
Ph.: +33 (0)4 73 67 06 70 Number of employees: 12
Ph.: +33 (0) 6 14 15 55 52 Activity: R&D services
fb@aptys-pharmaceuticals.com Key-words: formulation, transdermal, topical, injectable
depot, peptide, QC, analytical development, valisations,
stability, ICH, GMP
www.aptys-pharmaceuticals.com
29ARIANA ARIANA is a leading Digital Health Company that helps
pharmaceutical and biotechnology partners adapt patient
PHARMACEUTICALS treatments to individual biological characteristics. Ariana has
a 15 year proven track record in Oncology, Alzheimer’s and
other therapeutic areas, using its KEM® Artificial Intelligence
technology to enable optimal patient stratification.
KEM® is the only FDA-tested technology that systematically
explores combinations of clinical data, Pharmaco Kinetic
and a broad range of omic biomarkers. Founded in 2003 as
a spin-off of the Institut Pasteur, Paris, France, the company
operates in the United States since 2012 and has announced
multiple collaborations with pharma and biotech companies.
Member of: Medicen Further information is available at www.arianapharma.com.
ARIANA PHARMACEUTICALS
43-47 avenue de La Grande Armée
750116 PARIS -France
Mohammad AFSHAR
Founder & CEO
Ph.: +33 (0)1 44 37 17 00
m.afshar@arianapharma.com Date of creation: 2003
Number of employees: 10
Local representative: Activity: Bioinformatics
ARIANA DATA INTELLIGENCE, Inc. Therapeutic area: Oncology – Alzheimer's - Other CNS –
One Broadway - 14th Floor Metabolic diseases – Immunology
CAMBRIDGE, MA 02142 Key-words: Artificial Intelligence - Precision Medicine -
Datamining – KEM - Big Data
www.arianapharma.com
ATLANTHERA ATLANTHERA is a drug discovery company focused on bone
diseases and has developed a unique bone-targeted drug
delivery technology.
Atlanthera has made its proof of concept of bone targeting
with its lead candidate in oncology, the new 12b80 molecule,
which is now ready for clinical development.
In parallel, our company is extending its therapeutic strategy
to the osteoarticular targeting of anti-rheumatoid drugs
(anti-inflammatory, antalgic and anti-chondrodegradation
strategies) as well as anti-microbial drugs.
Member of: Atlanpole Our objectives during BIO convention 2018: Licensing out
Biotherapies and co-development collaborations.
ATLANTHERA
3 rue Aronnax
44800 SAINT-HERBLAIN
France
Ph.: +33 (0)2 51 78 98 76
Elisabeth PORCHER
Business Development Manager
Ph.: +33 (0)2 51 78 98 76 Date of creation: 2011
Cel.: +33 (0)6 35 30 32 72 Number of employees: 11
elisabeth.porcher@atlanthera.com Activity: Drug discovery company
Therapeutic area: BONE DISEASES
Key-words: OSTEOSARCOMA, OSTEOARTHRITIS, PAIN,
INFLAMMATION, INFECTIOUS DISEASES
www.atlanthera.com
30You can also read
